Halozyme Therapeutics reported $1.25B in Debt for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Debt Change
DBV Technologies DBVT:US 0 0
Acadia Pharmaceuticals ACAD:US $ 0M 0M
Agios Pharmaceuticals AGIO:US $ 1.22M 0.7M
Alnylam Pharmaceuticals ALNY:US $ 677.72M 1.01M
Amarin AMRN:US $ 0M 0M
Amgen AMGN:US $ 36522M 332M
Aptinyx Inc APTX:US $ 24.5M 206K
Baxter International BAX:US $ 16686M 488M
Cara Therapeutics CARA:US $ 0 0
Cytokinetics CYTK:US $ 199.42M 1.44M
Eli Lilly And LLY:US $ 16813.8M 305M
Esperion Therapeutics ESPR:US $ 259.08M 402K
Halozyme Therapeutics HALO:US $ 1246.18M 368.53M
Intercept Pharmaceuticals ICPT:US $ 713.86M 3.03M
Intra Cellular Therapies ITCI:US $ 0M 0M
Intrexon XON:US $ 198.67M 2.79M
JAZZ PHA JAZZ:US $ 6021M 2.87M
Mannkind MNKD:US $ 376.46M 8.08M
Nektar Therapeutics NKTR:US $ 0M 0M
Peregrine Pharmaceuticals PPHM:US $ 142.31M 0.14M
Rigel Pharmaceuticals RIGL:US $ 29.84M 0.01M
United Therapeutics UTHR:US $ 800M 0M